


12 July 2012



ASX RELEASE:

NEWLY APPOINTED CEO STARTS AT IMPEDIMED

Brisbane, Australia. – **ImpediMed Limited** (ASX: IPD) (“the **Company** or **ImpediMed**”) is pleased to announce Richard Carreon, ImpediMed’s new CEO, has taken up his appointment on 10 July 2012 in San Diego. The Company previously announced changes to the executive team to shareholders and the market on 12 June 2012.

On 10 July 2012, the Board of Directors accepted Greg Brown’s resignation as CEO and MD. On the same date, the Board of Directors accepted Greg Brown’s consent to serve on the Company’s Board as an Executive Director, effective immediately.

ENDS

For further information contact:

Richard Carreon
Chief Executive Officer
T: +1(858) 412 0200
M: +1(619) 309-6230

Peggy Brooker
Chief Operating Officer & CFO
T: +1(858) 412 0200
M: +1(949) 735 6699

About L-Dex

L-Dex[®] is a trademark of ImpediMed Limited.

The L-Dex[®] scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm and leg in women and the leg in men by a medical provider. The L-Dex[®] scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au